12:00 AM
 | 
Jun 29, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Leukine sargramostim: Phase II data

In an open-label Phase II trial in 98 evaluable patients with stage II, III or IV melanoma, subcutaneous Leukine for up to 3 years following surgical resection was well tolerated. Five-year median melanoma-specific survival was 60%. Patients received 125...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >